A
Armata Pharmaceuticals, Inc. (ARMP)
ASE – Real Time Price. Currency in USD
9.00
+0.18 (2.04%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
9.00
+0.18 (2.04%)
At close: May 12, 2026, 4:00 PM EDT
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
| Name | Position |
|---|---|
| Dr. Deborah L. Birx M.D. | CEO & Director |
| Dr. Pierre Kyme Ph.D. | Chief Business Officer |
| Mr. David D. House | Senior VP of Finance & Principal Financial Officer |
| Mr. Peter Hubbard | Vice President of Operations |
| Ms. Bani Tchekanova Ph.D. | Head of Regulatory Strategy & Operations |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | tm2613773d1_8k.htm |
| 2026-04-27 | DEF 14A | armp-20260611xdef14a.htm |
| 2026-04-27 | 8-K | tm2610924d1_8k.htm |
| 2026-04-02 | 8-K | tm2610924d1_8k.htm |
| 2026-03-25 | 8-K | armp-20260325x8k.htm |
| 2026-03-25 | 10-K | armp-20251231x10k.htm |
| 2026-03-19 | 8-K | tm269341d1_8k.htm |
| 2026-02-23 | 8-K | tm267017d1_8k.htm |
| 2026-01-26 | 8-K | tm263967d1_8k.htm |
| 2026-01-13 | 8-K | tm262898d1_8k.htm |